Amiodarone Hci Injection, Solution
Product Images NDC 51662-1363

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Amiodarone Hci (NDC 51662-1363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse (Adverse)

This is a table presenting the adverse events reported in a study of 1836 patients involving an intervention. The study is open-label and event-controlled. The adverse events reported are categorized by body system, including Body as a Whole, Cardiovascular System, Digestive System, among others. For each adverse event, the number and percentage of patients who experienced it are provided. The adverse events reported include fever, bradycardia, congestive heart failure, heart arrest, hypotension, ventricular tachycardia, liver function tests abnormal, and nausea.*

FDA Label Image

Clinical (Clinc 1)

FDA Label Image

Clinical 2 (Clinic 2)

This appears to be a table showing drug clearance, as well as the volume of distribution and elimination half-life for two drugs: Amiodarone and Desethylamiodarone. Amiodarone has a drug clearance of 90-158 mL/h/kg, Vc of 0.2 L/kg, Vss of 40-84 L/kg, and an elimination half-life of 20-47 days. For Desethylamiodarone, drug clearance ranges from 197-290 mL/h/kg, Vc is not provided, Vss is 68-168 L/kg, and its elimination half-life is longer than Amiodarone's.*

FDA Label Image

Dosage 2 (Dosage 2)

This text describes the stability of Amiodarone HCl Injection Solution in two different containers: 5% Dextrose with PVC container and 5% Dextrose with Polyolefin and Glass container. The text provides information on the physical compatibility of the solution with and without amiodarone, and water loss at various time intervals and temperatures.*

FDA Label Image

Dosage 3 (Dosage 3)

This is a chart listing Y-site injection incompatibilities between various drug vehicles and concentrations of amiodarone. It includes information on the potential for precipitation or other comments for each combination.*

FDA Label Image

Dosage 4 (Dosage 4)

This text provides recommendations for the oral dosage of amiodarone after intravenous infusion, based on the duration of infusion. For infusions lasting less than a week, the initial daily dose of oral amiodarone is recommended to be between 800 and 1600 mg. For infusions lasting between 1 and 3 weeks, the daily dose should be between 600 and 800 mg, and for infusions lasting more than 3 weeks, the daily dose should be 400 mg. It should be noted that Amiodarone HCL Injection is not meant for long-term maintenance treatment.*

FDA Label Image

Dosage 1 (Dosage)

This is a set of dose recommendations for Amiodarone HCl Injection in the first 24 hours. The loading dose is 150mg, given over the first 10 minutes, followed by 360mg over the next 6 hours, and 540mg over the remaining 18 hours, with corresponding flow rates. The instructions include information on how to dilute the medication for IV infusion.*

FDA Label Image

How Supplied (How Supplied)

FDA Label Image

Logo (Logo)

APP Pharmaceuticals, LLC is a pharmaceutical company based in Schaumburg, IL 80173.*

FDA Label Image

Serialized Labeling (Serialized Labeling)

FDA Label Image

Structure (Structure)

FDA Label Image

Vial (Vial Label)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.